Effects of resveratrol on polycystic ovarian syndrome: a systematic review and meta-analysis of randomized controlled trials
- 11 August 2023
- journal article
- review article
- Published by Springer Nature in Endocrine
- Vol. 83 (1) , 51-59
Abstract
Purpose Polycystic ovarian syndrome (PCOS) is the heightened ovarian dysfunction associated with excessive androgen production, manifesting with hirsutism, abnormal menstrual cycle, and polycystic ovaries. In this systematic review and meta-analysis, the effect of resveratrol on laboratory parameters of PCOS women will be assessed. Methods An electronic search via PubMed, Cochrane Library, and Scopus was performed up to February 2023 for randomized controlled trials conforming to our pre-specified outcomes. A random-effects model was utilized, with cohorts compared using mean differences. Results Three randomized controlled trials (RCTs) were included, reporting 84 patients receiving resveratrol, and 85 patients receiving placebo. It was observed that resveratrol significantly improved prolactin levels (P = 0.02), acne scores (P = 0.008), and total cholesterol (P = 0.02). However, there were no significant improvements observed with respect to total testosterone, follicle stimulating hormone (FSH), lutenizing hormone (LH), body mass index (BMI), hirsutism scores, triglycerides, high-density lipoprotein (HDL), and low-density lipoprotein (LDL). Conclusion As per the results of our analysis, resveratrol demonstrates mild therapeutic potential for the sufferers of PCOS, and cannot replace the current established treatment guidelines. However, further comprehensive RCTs are required in order to assess the efficacy in long-term dosing and the safety profile of the use of resveratrol.Keywords
This publication has 42 references indexed in Scilit:
- Resveratrol inhibited GH3 cell growth and decreased prolactin level via estrogen receptorsClinical Neurology and Neurosurgery, 2012
- Dyslipidemia in PCOSSteroids, 2012
- Neuroendocrine dysfunction in polycystic ovary syndromeSteroids, 2012
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteriaHuman Reproduction, 2009
- Modulation of Gonadotropin-Releasing Hormone Pulse Generator Sensitivity to Progesterone Inhibition in Hyperandrogenic Adolescent Girls—Implications for Regulation of Pubertal MaturationThe Journal of Clinical Endocrinology & Metabolism, 2009
- The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force reportFertility and Sterility, 2009
- Pathophysiology and types of dyslipidemia in PCOSTrends in Endocrinology & Metabolism, 2007
- Suppression of the Nuclear Factor‐κB Activation Pathway by Spice‐Derived Phytochemicals: Reasoning for SeasoningAnnals of the New York Academy of Sciences, 2004
- Measuring inconsistency in meta-analysesBMJ, 2003